

Claims

1. A compound of the formula I, in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them,



I

wherein Ht is chosen from the series consisting of



;

G is chosen from the series consisting of R^{71}-O-C(O)-, R^{72}-N(R^{73})-C(O)-, NC- and tetrazol-5-yl;

R^1 is chosen from the series consisting of hydrogen, halogen, $(C_1$-$C_6)$-alkyl, CF_3, $(C_3$-$C_7)$-cycloalkyl-C_sH_{2s}-, Ar-C_sH_{2s}-, Ar-O, $(C_1$-$C_6)$-alkyl-O-, $(C_1$-$C_6)$-alkyl-$S(O)_m$- and NC-; wherein s is an integer chosen from the series consisting of 0, 1, 2 and 3;

R^2 is chosen from the series consisting of hydrogen, halogen, $(C_1$-$C_6)$-alkyl, CF_3, $(C_1$-$C_6)$-alkyl-O-, $(C_1$-$C_6)$-alkyl-$S(O)_m$- and NC-;

R^3 is chosen from the series consisting of hydrogen, $(C_1$-$C_6)$-alkyl;

R^4 is chosen from the series consisting of $(C_1$-$C_7)$-alkyl, $(C_3$-$C_7)$-cycloalkyl-C_sH_{2s}- and Ar-C_sH_{2s}-, wherein s is an integer chosen from the series consisting of 0, 1, 2 and 3;

R^5 is chosen from the series consisting of hydrogen, halogen, $(C_1$-$C_6)$-alkyl, $(C_1$-$C_6)$-alkyl-O-, $(C_1$-$C_6)$-alkyl-$S(O)_m$- and NC-;

R^{10} is chosen from the series consisting of R^{11}, Het^2-C(O)-, R^{14}-C(O)- and $(C_1$-$C_4)$-alkyl-$S(O)_m$-;

R^{11} is chosen from the series consisting of hydrogen, R^{14}, $(C_3$-$C_7)$-cycloalkyl, Ar and Het^3;

R^{14} is $(C_1$-$C_{10})$-alkyl which is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, HO-, R^{16}-O-, oxo, $(C_3$-$C_7)$-cycloalkyl, Ar, Het^1, Het^3, NC-, H_2N-C(O)-, $(C_1$-$C_4)$-alkyl-NH-C(O)-, di$((C_1$-$C_4)$-alkyl)N-C(O)-, Het^1-C(O)-, $(C_1$-$C_4)$-alkyl-C(O)-NH- and $(C_1$-$C_4)$-alkyl-$S(O)_m$-;

R^{16} is $(C_1$-$C_6)$-alkyl which is optionally substituted by one or more identical or different substituents chosen from the series consisting of HO-, $(C_1$-$C_4)$-alkyl-O- and NC-;

R^{30} is chosen from the series consisting of R^{31}, $(C_3$-$C_7)$-cycloalkyl, R^{32}-C_uH_{2u}- and Het^3-C_uH_{2u}-, wherein u is an integer chosen from the series consisting of 0, 1, 2 and 3;

R^{31} is $(C_1\text{-}C_{10})$-alkyl which is substituted by one or more identical or different substituents chosen from the series consisting of halogen, $(C_3\text{-}C_7)$-cycloalkyl, HO-, $(C_1\text{-}C_6)$-alkyl-O-, $(C_1\text{-}C_6)$-alkyl-$S(O)_m$- and NC-;

R^{32} is chosen from the series consisting of phenyl and an aromatic 5-membered or 6-membered monocyclic heterocycle which comprises one, two or three identical or different ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur and is bonded via a ring carbon atom, wherein the phenyl and the heterocycle all are optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, $(C_1\text{-}C_6)$-alkyl, $(C_3\text{-}C_7)$-cycloalkyl, HO-, $(C_1\text{-}C_6)$-alkyl-O-, R^{33}-O-, R^{33}-$(C_1\text{-}C_4)$-alkyl-O-, -O-CH_2-O-, -O-CF_2-O-, $(C_1\text{-}C_6)$-alkyl-$S(O)_m$-, H_2N-$S(O)_2$-, $(C_1\text{-}C_4)$-alkyl-NH-$S(O)_2$-, di$((C_1\text{-}C_4)$-alkyl)N-$S(O)_2$-, H_2N-, $(C_1\text{-}C_6)$-alkyl-NH-, di$((C_1\text{-}C_6)$-alkyl)N-, Het^1, $(C_1\text{-}C_4)$-alkyl-C(O)-NH-, Ar-C(O)-NH-, $(C_1\text{-}C_4)$-alkyl-$S(O)_2$-NH- and NC-;

R^{33} is chosen from the series consisting of phenyl and an aromatic 5-membered or 6-membered monocyclic heterocycle which comprises one, two or three identical or different ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur and is bonded via a ring carbon atom, wherein the phenyl and the heterocycle all are optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, $(C_1\text{-}C_6)$-alkyl, $(C_3\text{-}C_7)$-cycloalkyl, HO-, $(C_1\text{-}C_6)$-alkyl-O-, $(C_1\text{-}C_6)$-alkyl-$S(O)_m$-, H_2N-$S(O)_2$-, $(C_1\text{-}C_4)$-alkyl-NH-$S(O)_2$-, di$((C_1\text{-}C_4)$-alkyl)N-$S(O)_2$- and NC-;

R^{40} is chosen from the series consisting of hydrogen and $(C_1\text{-}C_4)$-alkyl;

or R^{30} and R^{40} together are $(CH_2)_x$ which is optionally substituted by one or more identical or different $(C_1\text{-}C_4)$-alkyl substituents, wherein x is an integer chosen from the series consisting of 2, 3, 4 and 5;

R^{50} is chosen from the series consisting of hydrogen, $(C_1\text{-}C_6)$-alkyl, HO- and $(C_1\text{-}C_6)$-alkyl-O-;

R^{60} is chosen from the series consisting of hydrogen and $(C_1$-$C_6)$-alkyl;

or R^{50} and R^{60} together are $(CH_2)_y$ which is optionally substituted by one or more identical or different $(C_1$-$C_4)$-alkyl substituents, wherein y is an integer chosen from the series consisting of 2, 3, 4 and 5;

or R^{30} and R^{50} together are $(CH_2)_z$ which is optionally substituted by one or more identical or different $(C_1$-$C_4)$-alkyl substituents, wherein z is an integer chosen from the series consisting of 2, 3, 4 and 5;

R^{71} is chosen from the series consisting of hydrogen and $(C_1$-$C_8)$-alkyl which is optionally substituted by one or more identical or different substituents chosen from the series consisting $(C_1$-$C_6)$-alkyl-O- and $(C_1$-$C_6)$-alkyl-C(O)-O-;

R^{72} is chosen from the series consisting of hydrogen, $(C_1$-$C_6)$-alkyl, $(C_3$-$C_6)$-cycloalkyl, $–CH_2$-$(CH_2)_b$-$(C_3$-$C_6)$-cycloalkyl, Het^4 and -$(CH_2)_b$-Het^4, where alkyl or cycloalkyl is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, HO-, HOOC-, $(C_1$-$C_6)$-alkyl-O- and $(C_1$-$C_6)$-alkyl-C(O)-O-, NC-, $N((C_1$-$C_4)$-alkyl$)_2$ and b is 0, 1 or 2;

R^{73} is chosen from the series consisting of hydrogen, $(C_1$-$C_6)$-alkyl;

or

R^{72} and R^{73} together with the nitrogen atom to which they are bonded form a saturated 4-membered to 7-membered monocyclic heterocycle, which contain optionally one further ring heteroatom chosen from the series consisting of nitrogen, oxygen and sulfur, which is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, $(C_1$-$C_4)$-alkyl, HO- and $(C_1$-$C_4)$-alkyl-O-;

Ar, independently of each other group Ar, is chosen from the series consisting of phenyl and an aromatic 5-membered or 6-membered monocyclic heterocycle which comprises one, two or three identical or different ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur and is bonded via a ring carbon atom, wherein the phenyl and the heterocycle all are optionally substituted by one or more

identical or different substituents chosen from the series consisting of halogen, (C_1-C_6)-alkyl, (C_1-C_6)-alkyl-O-, -O-CH_2-O-, O-CH_2-CH_2-O-, -O-CF_2-O-, (C_1-C_6)-alkyl-S(O)$_m$-, H_2N-S(O)$_2$-, CF_3 and NC-;

Het^1, independently of each other group Het^1, is a saturated or unsaturated 4-membered to 8-membered monocyclic heterocycle which comprises a ring nitrogen atom via which Het^1 is bonded and optionally one or two identical or different further ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur, which is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (C_1-C_4)-alkyl, HO-, (C_1-C_4)-alkyl-O-, oxo and NC-;

Het^2 is a saturated 4-membered to 7-membered monocyclic heterocycle which comprises a ring nitrogen atom via which Het^2 is bonded and optionally one further ring heteroatom chosen from the series consisting of nitrogen, oxygen and sulfur, which is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (C_1-C_4)-alkyl, HO-, oxo and (C_1-C_4)-alkyl-O-;

Het^3, independently of each other group Het^3, is a saturated 4-membered to 7-membered monocyclic heterocycle which comprises one or two identical or different ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur and is bonded via a ring carbon atom, which is optionally substituted by one or more identical or different substituents chosen from the series consisting of fluorine, (C_1-C_4)-alkyl and oxo;


Het^4, independently of each other group Het^4, is a saturated or unsaturated 4-membered to 8-membered monocyclic heterocycle which comprises one to four ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur which is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (C_1-C_4)-alkyl, HO-, (C_1-C_4)-alkyl-O-, oxo and NC-;

m, independently of each other number m, is an integer chosen from the series consisting of 0, 1 and 2;

wherein all cycloalkyl groups, independently of each other, are optionally substituted by one or more identical or different substituents chosen from the series consisting of fluorine and $(C_1$-$C_4)$-alkyl;

wherein all alkyl, C_sH_{2s}, C_uH_{2u}, $(CH_2)_x$ and $(CH_2)_y$ groups, independently of each other, and independently of any other substituents, are optionally substituted by one or more fluorine substituents.

2. A compound of the formula I, in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them, as claimed in claim 1, wherein Ht is chosen from the series consisting of



;

R^1 is chosen from the series consisting of hydrogen, halogen, $(C_1$-$C_6)$-alkyl, CF_3, $(C_3$-$C_7)$-cycloalkyl-C_sH_{2s}-, Ar-C_sH_{2s}-, Ar-O, $(C_1$-$C_6)$-alkyl-O-; wherein s is an integer chosen from the series consisting of 0, 1, 2 and 3;

R^2 is chosen from the series consisting of hydrogen, halogen, $(C_1$-$C_6)$-alkyl, CF_3, $(C_1$-$C_6)$-alkyl-O- and NC-;

R^3 is chosen from the series consisting of hydrogen, $(C_1\text{-}C_6)$-alkyl;

R^4 is chosen from the series consisting of $(C_1\text{-}C_7)$-alkyl, $(C_3\text{-}C_7)$-cycloalkyl-C_sH_{2s}- and Ar-C_sH_{2s}-, wherein s is an integer chosen from the series consisting of 0, 1, 2 and 3;

R^5 is chosen from the series consisting of hydrogen, halogen, $(C_1\text{-}C_6)$-alkyl, $(C_1\text{-}C_6)$-alkyl-O-, and NC-;

3. A compound of the formula I, in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them, as claimed in any one or more of claims 1 and 2, wherein

R^{30} is R^{32}-C_uH_{2u}-, wherein u is an integer chosen from the series consisting of 0 and 1;

R^{32} is chosen from the series consisting of phenyl and an aromatic 5-membered or 6-membered monocyclic heterocycle which comprises one, two or three identical or different ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur and is bonded via a ring carbon atom, wherein the phenyl and the heterocycle all are optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, $(C_1\text{-}C_6)$-alkyl, $(C_3\text{-}C_7)$-cycloalkyl, HO-, $(C_1\text{-}C_6)$-alkyl-O-, R^{33}-O-, R^{33}-$(C_1\text{-}C_4)$-alkyl-O-, -O-CH_2-O-, -O-CF_2-O-, $(C_1\text{-}C_6)$-alkyl-$S(O)_m$-, H_2N-$S(O)_2$-, $(C_1\text{-}C_4)$-alkyl-NH-$S(O)_2$-, di$((C_1\text{-}C_4)$-alkyl)N-$S(O)_2$-, H_2N-, $(C_1\text{-}C_6)$-alkyl-NH-, di$((C_1\text{-}C_6)$-alkyl)N-, Het^1, $(C_1\text{-}C_4)$-alkyl-C(O)-NH-, Ar-C(O)-NH-, $(C_1\text{-}C_4)$-alkyl-$S(O)_2$-NH- and NC-;

R^{33} is chosen from the series consisting of phenyl and an aromatic 5-membered or 6-membered monocyclic heterocycle which comprises one, two or three identical or different ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur and is bonded via a ring carbon atom, wherein the phenyl and the heterocycle all are optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, $(C_1\text{-}C_6)$-alkyl, $(C_3\text{-}C_7)$-cycloalkyl, HO-, $(C_1\text{-}C_6)$-alkyl-O-, $(C_1\text{-}C_6)$-alkyl-$S(O)_m$-, H_2N-$S(O)_2$-, $(C_1\text{-}C_4)$-alkyl-NH-$S(O)_2$-, di$((C_1\text{-}C_4)$-alkyl)N-$S(O)_2$- and NC-;

R^{40} is hydrogen.

4. A compound of the formula I, in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them, as claimed in any one or more of claims 1 to 3, wherein

G is R^{71}-O-C(O)- and R^{72}-N(R^{73})-C(O)-;

R^{71} is chosen from the series consisting of hydrogen and (C_1-C_8)-alkyl;

R^{72} is chosen from the series consisting of hydrogen, (C_1-C_6)-alkyl;

R^{73} is chosen from the series consisting of hydrogen, (C_1-C_6)-alkyl.

5. A compound of the formula I, in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them, as claimed in any one or more of claims 1 to 4, wherein

R^{50} is hydrogen;

R^{60} is hydrogen.

6. A compound of the formula I, in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them, as claimed in any one or more of claims 1 to 5, wherein

R^{30} is R^{32}-C_uH_{2u}- wherein u is an integer 0;

R^{40} is hydrogen,

7. A compound of the formula I, in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, or a

physiologically acceptable solvate of any of them, as claimed in any one or more of claims 1 to 6, wherein the compound is chosen from

(S)-3-[(2-Phenyl-1H-imidazole-4-carbonyl)-amino]-3-o-tolyl-propionic acid

(S)-3-[(5-Phenyl-isoxazole-3-carbonyl)-amino]-3-o-tolyl-propionic acid

3-Cyclohexyl-3-[(5-methyl-2-phenyl-oxazole-4-carbonyl)-amino]-propionic acid

3-[(5-Methyl-2-phenyl-oxazole-4-carbonyl)-amino]-4-phenyl-butyric acid

(S)-3-[(5-Methyl-2-phenyl-oxazole-4-carbonyl)-amino]-3-o-tolyl-propionic acid

(S)-3-[(1-Isopropyl-1H-indazole-3-carbonyl)-amino]-3-o-tolyl-propionic acid

(S)-3-(2-Fluoro-phenyl)-3-[(5-methyl-2-phenyl-oxazole-4-carbonyl)-amino]-propionic acid

(S)-3-(3-Fluoro-phenyl)-3-[(5-methyl-2-phenyl-oxazole-4-carbonyl)-amino]-propionic acid

(S)-3-(4-Fluoro-phenyl)-3-[(5-methyl-2-phenyl-oxazole-4-carbonyl)-amino]-propionic acid

(S)-3-{[2-(2-Fluoro-phenyl)-5-methyl-oxazole-4-carbonyl]-amino}-3-phenyl-propionic acid

(R)-3-{[3-(2-Fluoro-phenyl)-[1,2,4]oxadiazole-5-carbonyl]-amino}-4-phenyl-butyric acid

(S)-3-{[5-(2-Fluoro-phenyl)-[1,2,4]oxadiazole-3-carbonyl]-amino}-3-p-tolyl-propionic acid

(R)-3-{[5-(2-Fluoro-phenyl)-[1,2,4]oxadiazole-3-carbonyl]-amino}-4-phenyl-butyric acid

(S)-3-{[5-(2-Fluoro-phenyl)-[1,2,4]oxadiazole-3-carbonyl]-amino}-3-phenyl-butyric acid

(S)-3-{[5-(2-Fluoro-phenyl)-[1,2,4]oxadiazole-3-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-{[5-(2-Fluoro-phenyl)-[1,2,4]oxadiazole-3-carbonyl]-amino}-3-m-tolyl-propionic acid

(S)-3-(2-Fluoro-phenyl)-3-{[5-(2-fluoro-phenyl)-[1,2,4]oxadiazole-3-carbonyl]-amino}-propionic acid

(S)-3-(3-Fluoro-phenyl)-3-{[5-(2-fluoro-phenyl)-[1,2,4]oxadiazole-3-carbonyl]-amino}-propionic acid

(S)-3-(4-Fluoro-phenyl)-3-{[5-(2-fluoro-phenyl)-[1,2,4]oxadiazole-3-carbonyl]-amino}-propionic acid

(S)-3-{[5-(2,3-Difluoro-phenyl)-[1,2,4]oxadiazole-3-carbonyl]-amino}-3-phenyl-propionic acid

(S)-3-[(1-Ethyl-5-phenyl-1H-pyrazole-3-carbonyl)-amino]-3-o-tolyl-propionic acid

(S)-3-[(5-Isopropyl-2-phenyl-oxazole-4-carbonyl)-amino]-3-phenyl-propionic acid

(S)-3-(4-Methoxy-phenyl)-3-[(5-methyl-2-phenyl-oxazole-4-carbonyl)-amino]-propionic acid

(S)-3-(3-Methoxy-phenyl)-3-[(5-methyl-2-phenyl-oxazole-4-carbonyl)-amino]-propionic acid

(S)-3-{[2-(2-Fluoro-phenyl)-5-methyl-oxazole-4-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-{[5-(4-Chloro-phenyl)-isoxazole-3-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-{[2-(2-Fluoro-phenyl)-5-methyl-oxazole-4-carbonyl]-amino}-3-m-tolyl-propionic acid

(S)-3-(3-Chloro-phenyl)-3-[(5-methyl-2-phenyl-oxazole-4-carbonyl)-amino]-propionic acid

(R)-3-{[2-(2-Fluoro-phenyl)-5-methyl-oxazole-4-carbonyl]-amino}-4-phenyl-butyric acid

(S)-3-{[2-(2-Fluoro-phenyl)-5-methyl-oxazole-4-carbonyl]-amino}-3-phenyl-butyric acid

(S)-3-{3-[3-(2-Fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-propionylamino}-3-phenyl-propionic acid

(S)-3-(2-Chloro-phenyl)-3-[(5-methyl-2-phenyl-oxazole-4-carbonyl)-amino]-propionic acid

(S)-3-{[1-(2-Chloro-phenyl)-5-methyl-1H-[1,2,4]triazole-3-carbonyl]-amino}-3-phenyl-propionic acid

3-Cyclohexyl-3-[(5-isopropyl-2-phenyl-oxazole-4-carbonyl)-amino]-propionic acid

(S)-3-(2-Fluoro-phenyl)-3-{[2-(2-fluoro-phenyl)-5-methyl-oxazole-4-carbonyl]-amino}-propionic acid

(S)-3-(3-Fluoro-phenyl)-3-{[2-(2-fluoro-phenyl)-5-methyl-oxazole-4-carbonyl]-amino}-propionic acid

(S)-3-(4-Fluoro-phenyl)-3-{[2-(2-fluoro-phenyl)-5-methyl-oxazole-4-carbonyl]-amino}-propionic acid

(S)-3-{[5-(2,3-Difluoro-phenyl)-[1,2,4]oxadiazole-3-carbonyl]-amino}-3-p-tolyl-propionic acid

(S)-3-{[5-(2,3-Difluoro-phenyl)-[1,2,4]oxadiazole-3-carbonyl]-amino}-3-m-tolyl-propionic acid

(S)-3-{[5-(2,3-Difluoro-phenyl)-[1,2,4]oxadiazole-3-carbonyl]-amino}-3-phenyl-butyric acid

(R)-3-{[5-(2,3-Difluoro-phenyl)-[1,2,4]oxadiazole-3-carbonyl]-amino}-4-phenyl-butyric acid

(S)-3-{[5-(2,3-Difluoro-phenyl)-[1,2,4]oxadiazole-3-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-{[5-(2,3-Difluoro-phenyl)-[1,2,4]oxadiazole-3-carbonyl]-amino}-3-(2-fluoro-phenyl)-propionic acid

(S)-3-{[5-(2,3-Difluoro-phenyl)-[1,2,4]oxadiazole-3-carbonyl]-amino}-3-(4-fluoro-phenyl)-propionic acid

3-[(5-Isopropyl-2-phenyl-oxazole-4-carbonyl)-amino]-4-phenyl-butyric acid

(S)-3-[(5-Dimethylsulfamoyl-2-methyl-furan-3-carbonyl)-amino]-3-o-tolyl-propionic acid

(S)-3-(2-Fluoro-phenyl)-3-[(5-isopropyl-2-phenyl-oxazole-4-carbonyl)-amino]-propionic acid

(S)-3-(4-Fluoro-phenyl)-3-[(5-isopropyl-2-phenyl-oxazole-4-carbonyl)-amino]-propionic acid

(R)-3-{3-[3-(2-Fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-propionylamino}-4-phenyl-butyric acid

(S)-3-{3-[3-(2-Fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-propionylamino}-3-m-tolyl-propionic acid

(S)-3-{3-[3-(2-Fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-propionylamino}-3-phenyl-butyric acid

(S)-3-{3-[3-(2-Fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-propionylamino}-3-p-tolyl-propionic acid

(S)-3-{3-[3-(2-Fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-propionylamino}-3-o-tolyl-propionic acid

(S)-Cyclohexyl-{[5-(4-trifluoromethyl-pyridin-3-yl)-[1,2,4]oxadiazole-3-carbonyl]-amino}-acetic acid

(S)-3-{[1-(2-Chloro-phenyl)-5-methyl-1H-[1,2,4]triazole-3-carbonyl]-amino}-3-p-tolyl-propionic acid

(S)-3-{[1-(2-Chloro-phenyl)-5-ethyl-1H-[1,2,4]triazole-3-carbonyl]-amino}-3-phenyl-propionic acid

(S)-3-{[1-(2-Chloro-phenyl)-5-methyl-1H-[1,2,4]triazole-3-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-(4-Fluoro-phenyl)-3-{3-[3-(2-fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-propionylamino}-propionic acid

(S)-3-(2-Fluoro-phenyl)-3-{3-[3-(2-fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-propionylamino}-propionic acid

(S)-3-(3-Fluoro-phenyl)-3-{3-[3-(2-fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-propionylamino}-propionic acid

(S)-3-(3-Chloro-phenyl)-3-{[2-(2-fluoro-phenyl)-5-methyl-oxazole-4-carbonyl]-amino}-propionic acid

3-(2-Chloro-phenyl)-3-{[2-(2-fluoro-phenyl)-5-methyl-oxazole-4-carbonyl]-amino}-propionic acid

(S)-3-(4-Chloro-phenyl)-3-{[2-(2-fluoro-phenyl)-5-methyl-oxazole-4-carbonyl]-amino}-propionic acid

(S)-3-{[1-Methyl-4-(propane-1-sulfonylamino)-1H-pyrazole-3-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-[(5-Isopropyl-2-phenyl-oxazole-4-carbonyl)-amino]-3-(3-methoxy-phenyl)-propionic acid

(S)-3-(2,3-Dimethoxy-phenyl)-3-[(5-methyl-2-phenyl-oxazole-4-carbonyl)-amino]-propionic acid

(S)-3-(2-Chloro-phenyl)-3-[(5-isopropyl-2-phenyl-oxazole-4-carbonyl)-amino]-propionic acid

3-Cyclohexyl-3-[(2-phenyl-5-trifluoromethyl-oxazole-4-carbonyl)-amino]-propionic acid

(S)-3-[(1,5-Diphenyl-1H-[1,2,4]triazole-3-carbonyl)-amino]-3-phenyl-propionic acid

(S)-3-{[1-(2-Chloro-phenyl)-5-ethyl-1H-[1,2,4]triazole-3-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-{[1-(2-Chloro-phenyl)-5-ethyl-1H-[1,2,4]triazole-3-carbonyl]-amino}-3-p-tolyl-propionic acid

(S)-3-[(1-Benzyl-1H-indazole-3-carbonyl)-amino]-3-o-tolyl-propionic acid

(S)-3-{3-[3-(2-Fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-propionylamino}-3-(4-methoxy-phenyl)-propionic acid

(S)-3-(3-Chloro-phenyl)-3-{3-[3-(2-fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-propionylamino}-propionic acid

(S)-3-(2,4-Dichloro-phenyl)-3-[(5-methyl-2-phenyl-oxazole-4-carbonyl)-amino]-propionic acid

(S)-3-(2,3-Dichloro-phenyl)-3-[(5-methyl-2-phenyl-oxazole-4-carbonyl)-amino]-propionic acid

(S)-3-[(2-Phenyl-5-trifluoromethyl-oxazole-4-carbonyl)-amino]-3-o-tolyl-propionic acid

(S)-3-[(5-Methyl-2-phenyl-oxazole-4-carbonyl)-amino]-3-(2-trifluoromethyl-phenyl)-propionic acid

(S)-3-(3-Fluoro-phenyl)-3-[(2-phenyl-5-trifluoromethyl-oxazole-4-carbonyl)-amino]-propionic acid

(S)-3-{[5-(2-Fluoro-phenyl)-[1,2,4]oxadiazole-3-carbonyl]-amino}-3-(2-trifluoromethyl-phenyl)-propionic acid

(S)-3-{[5-(2-Fluoro-phenyl)-[1,2,4]oxadiazole-3-carbonyl]-amino}-3-(3-trifluoromethyl-phenyl)-propionic acid

(S)-3-{[1-(2-Chloro-phenyl)-5-cyclopropyl-1H-[1,2,4]triazole-3-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-{[1-(2-Chloro-phenyl)-5-cyclopropyl-1H-[1,2,4]triazole-3-carbonyl]-amino}-3-p-tolyl-propionic acid

(S)-3-[(1,5-Diphenyl-1H-[1,2,4]triazole-3-carbonyl)-amino]-3-o-tolyl-propionic acid

(S)-3-{[1-(2-Chloro-phenyl)-5-isopropyl-1H-[1,2,4]triazole-3-carbonyl]-amino}-3-p-tolyl-propionic acid

3-[(1,5-Diphenyl-1H-[1,2,4]triazole-3-carbonyl)-amino]-4-phenyl-butyric acid

(S)-3-{[1-(2-Chloro-phenyl)-5-isopropyl-1H-[1,2,4]triazole-3-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-{[1-(2-Chloro-phenyl)-5-propyl-1H-[1,2,4]triazole-3-carbonyl]-amino}-3-p-tolyl-propionic acid

(S)-3-{[1-(2-Chloro-phenyl)-5-propyl-1H-[1,2,4]triazole-3-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-[(1,5-Diphenyl-1H-[1,2,4]triazole-3-carbonyl)-amino]-3-(2-fluoro-phenyl)-propionic acid

(S)-3-[(1,5-Diphenyl-1H-[1,2,4]triazole-3-carbonyl)-amino]-3-(4-fluoro-phenyl)-propionic acid

(S)-3-{[2-(2-Fluoro-phenyl)-5-methyl-oxazole-4-carbonyl]-amino}-3-(3-trifluoromethyl-phenyl)-propionic acid

(S)-3-{[2-(2-Fluoro-phenyl)-5-methyl-oxazole-4-carbonyl]-amino}-3-(4-trifluoromethyl-phenyl)-propionic acid

(S)-3-(2,3-Dichloro-phenyl)-3-{[2-(2-fluoro-phenyl)-5-methyl-oxazole-4-carbonyl]-amino}-propionic acid

(S)-3-{[4-(2,2-Dimethyl-propane-1-sulfonylamino)-1-methyl-1H-pyrazole-3-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-(3-Chloro-phenyl)-3-[(2-phenyl-5-trifluoromethyl-oxazole-4-carbonyl)-amino]-propionic acid

(S)-3-(2-Chloro-phenyl)-3-[(2-phenyl-5-trifluoromethyl-oxazole-4-carbonyl)-amino]-propionic acid

(S)-3-[(1-Benzyl-5-phenyl-1H-pyrazole-3-carbonyl)-amino]-3-o-tolyl-propionic acid

(S)-3-(4-Chloro-phenyl)-2-{[5-(4-trifluoromethyl-pyridin-3-yl)-[1,2,4]oxadiazole-3-carbonyl]-amino}-propionic acid

(S)-3-{[1-Ethyl-5-(2-propyl-piperidine-1-carbonyl)-1H-pyrazole-3-carbonyl]-amino}-3-phenyl-propionic acid

(S)-3-{[5-(2,3-Difluoro-phenyl)-[1,2,4]oxadiazole-3-carbonyl]-amino}-3-(2-trifluoromethyl-phenyl)-propionic acid

(S)-3-[(1,5-Diphenyl-1H-[1,2,4]triazole-3-carbonyl)-amino]-3-(3-methoxy-phenyl)-propionic acid

(S)-3-(2,3-Dichloro-phenyl)-3-[(5-isopropyl-2-phenyl-oxazole-4-carbonyl)-amino]-propionic acid

(S)-3-(3-Chloro-phenyl)-3-[(1,5-diphenyl-1H-[1,2,4]triazole-3-carbonyl)-amino]-propionic acid

(S)-3-(2,4-Dichloro-phenyl)-3-[(5-isopropyl-2-phenyl-oxazole-4-carbonyl)-amino]-propionic acid

(S)-3-(2-Chloro-phenyl)-3-[(1,5-diphenyl-1H-[1,2,4]triazole-3-carbonyl)-amino]-propionic acid

(S)-3-{[1-(2,6-Dichloro-phenyl)-5-ethyl-1H-[1,2,4]triazole-3-carbonyl]-amino}-3-p-tolyl-propionic acid

(S)-3-{[1-(2,6-Dichloro-phenyl)-5-ethyl-1H-[1,2,4]triazole-3-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-[(4-Cyclohexylmethanesulfonylamino-1-methyl-1H-pyrazole-3-carbonyl)-amino]-3-phenyl-propionic acid

(S)-3-{3-[3-(2-Fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-propionylamino}-3-(2-trifluoromethyl-phenyl)-propionic acid

(S)-3-{3-[3-(2-Fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-propionylamino}-3-(4-trifluoromethyl-phenyl)-propionic acid

(S)-3-(2,3-Dichloro-phenyl)-3-{3-[3-(2-fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-propionylamino}-propionic acid

(S)-3-{3-[3-(2-Fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-propionylamino}-3-(3-trifluoromethyl-phenyl)-propionic acid

(S)-3-{[1-Ethyl-5-(2-propyl-piperidine-1-carbonyl)-1H-pyrazole-3-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-{[1-Ethyl-5-(2-propyl-piperidine-1-carbonyl)-1H-pyrazole-3-carbonyl]-amino}-3-p-tolyl-propionic acid

(S)-3-{[1-Ethyl-5-(2-propyl-piperidine-1-carbonyl)-1H-pyrazole-3-carbonyl]-amino}-3-m-tolyl-propionic acid

(S)-3-[(1-Methyl-4-phenylmethanesulfonylamino-1H-pyrazole-3-carbonyl)-amino]-3-o-tolyl-propionic acid

(S)-3-{[1-(4-Fluoro-benzyl)-5-phenyl-1H-pyrazole-3-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-[(4-Cyclohexylmethanesulfonylamino-1-methyl-1H-pyrazole-3-carbonyl)-amino]-3-o-tolyl-propionic acid

(S)-3-(2,3-Dimethoxy-phenyl)-3-[(2-phenyl-5-trifluoromethyl-oxazole-4-carbonyl)-amino]-propionic acid

(S)-3-{[1-Methyl-4-(2-phenyl-ethanesulfonylamino)-1H-pyrazole-3-carbonyl]-amino}-3-o-tolyl-propionic acid


(S)-3-(2,3-Dichloro-phenyl)-3-[(2-phenyl-5-trifluoromethyl-oxazole-4-carbonyl)-amino]-propionic acid

(S)-3-(2,4-Dichloro-phenyl)-3-[(2-phenyl-5-trifluoromethyl-oxazole-4-carbonyl)-amino]-propionic acid

(S)-3-(2,3-Dichloro-phenyl)-3-[(1,5-diphenyl-1H-[1,2,4]triazole-3-carbonyl)-amino]-propionic acid

(S)-3-(2,4-Dichloro-phenyl)-3-[(1,5-diphenyl-1H-[1,2,4]triazole-3-carbonyl)-amino]-propionic acid.

8. A process for the preparation of a compound of the formula I or a physiologically acceptable salt thereof or a physiologically solvate of any of them as claimed in any one or more of claims 1 to 7, comprising reacting a compound of the formula II with a compound of the formula III,



II III I

wherein the groups Ht, G, R^{10}, R^{11}, R^{30}, R^{40}, R^{50} and R^{60} in the compounds of the formulae II and III are defined as in the compounds of the formula I and additionally functional groups can be present in protected form or in the form of a precursor group, and the group J in the compound of the formula II is HO-, (C_1-C_4)-alkyl-O- or halogen.

9. A compound of the formula I as claimed in any one or more of claims 1 to 7 or a physiologically acceptable salt thereof or a physiologically acceptable solvate of any of them for use as a pharmaceutical.


10. A pharmaceutical composition, which comprises at least one compound of the formula I as claimed in any one or more of claims 1 to 7 or a physiologically acceptable

salt thereof or a physiologically acceptable solvate of any of them and a pharmaceutically acceptable carrier.

11. Use of a compound of the formula I as claimed in any one or more of claims 1 to 7 or a physiologically acceptable salt thereof or a physiologically acceptable solvate of any of them for the manufacture of a medicament for the treatment of heart failure, congestive heart failure, cardiomyopathy, myocardial infarction, left ventricular dysfunction, cardiac hypertrophy, valvular heart diseases, hypertension, atherosclerosis, peripheral arterial occlusive disease, restenosis, vasvular permeability disorders, treatment of edema, thrombosis, rheumatoid arthritis, osteoarthritis, renal failure, cystic fibrosis, chronic bronchitis, chronic obstructive pulmonary disease, asthma, immunological diseases, diabetic complications, fibrotic diseases, pain, ischemia or reperfusion damage or neurodegenerative diseases, or for cardioprotection or renoprotection or as a diuretic (stand-alone treatment or in combination with established diuretics).


Claims

1. A compound of the formula I, in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof,



I

wherein Ht is chosen from the series consisting of



;

G is R^{71}-O-C(O)-;

R^1 is chosen from the series consisting of hydrogen, halogen, (C_1-C_6)-alkyl, CF_3, (C_3-C_7)-cycloalkyl-C_sH_{2s}-, Ar-C_sH_{2s}-, Ar-O, (C_1-C_6)-alkyl-O-, (C_1-C_6)-alkyl-$S(O)_m$- and NC-; wherein s is an integer chosen from the series consisting of 0, 1, 2 and 3;

R^2 is chosen from the series consisting of hydrogen, halogen, (C_1-C_6)-alkyl, CF_3, (C_1-C_6)-alkyl-O-, (C_1-C_6)-alkyl-$S(O)_m$- and NC-;

R^{10} is chosen from the series consisting of R^{11}

R^{11} is Ar;

R^{30} is chosen from the series consisting of (C_3-C_7)-cycloalkyl, and R^{32}-C_uH_{2u}-, wherein u is an integer chosen from the series consisting of 0, 1, 2 and 3;

R^{32} is chosen from the series consisting of phenyl and an aromatic 5-membered or 6-membered monocyclic heterocycle which comprises one, two or three identical or different ring heteroatoms chosen from the series consisting of nitrogen, oxygen and

sulfur and is bonded via a ring carbon atom, wherein the phenyl and the heterocycle all are optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, $(C_1$-$C_6)$-alkyl, $(C_3$-$C_7)$-cycloalkyl, HO-, $(C_1$-$C_6)$-alkyl-O-, -O-CH_2-O-, -O-CF_2-O-, $(C_1$-$C_6)$-alkyl-$S(O)_m$-, H_2N-$S(O)_2$-, $(C_1$-$C_4)$-alkyl-NH-$S(O)_2$-, di$((C_1$-$C_4)$-alkyl)N-$S(O)_2$-, H_2N-, $(C_1$-$C_6)$-alkyl-NH-, di$((C_1$-$C_6)$-alkyl)N-, $(C_1$-$C_4)$-alkyl-C(O)-NH-, $(C_1$-$C_4)$-alkyl-$S(O)_2$-NH- and NC-;

R^{40} is chosen from the series consisting of hydrogen and $(C_1$-$C_4)$-alkyl;

R^{50} is chosen from the series consisting of hydrogen, $(C_1$-$C_6)$-alkyl, HO- and $(C_1$-$C_6)$-alkyl-O-;

R^{60} is chosen from the series consisting of hydrogen and $(C_1$-$C_6)$-alkyl;

R^{71} is hydrogen;


Ar, independently of each other group Ar, is chosen from the series consisting of phenyl and an aromatic 5-membered or 6-membered monocyclic heterocycle which comprises one, two or three identical or different ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur and is bonded via a ring carbon atom, wherein the phenyl and the heterocycle all are optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, $(C_1$-$C_6)$-alkyl, $(C_1$-$C_6)$-alkyl-O-, -O-CH_2-O-, O-CH_2-CH_2-O-, -O-CF_2-O-, $(C_1$-$C_6)$-alkyl-$S(O)_m$-, H_2N-$S(O)_2$-, CF_3 and NC-;

m, independently of each other number m, is an integer chosen from the series consisting of 0, 1 and 2;

wherein all cycloalkyl groups, independently of each other, are optionally substituted by one or more identical or different substituents chosen from the series consisting of fluorine and $(C_1$-$C_4)$-alkyl;

wherein all alkyl, C_sH_{2s}, C_uH_{2u}, $(CH_2)_x$ and $(CH_2)_y$ groups, independently of each other, and independently of any other substituents, are optionally substituted by one or more fluorine substituents.

2. A compound of the formula I-2, in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, as claimed in claim 1, wherein



I-2 ;

R^2 is chosen from the series consisting of hydrogen, halogen, $(C_1$-$C_6)$-alkyl, CF_3, $(C_1$-$C_6)$-alkyl-O- and NC-.

3. A compound of the formula I, in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, as claimed in any one or more of claims 1 and 2, wherein

R^{30} is R^{32}-C_uH_{2u}-, wherein u is an integer chosen from the series consisting of 0 and 1;

R^{32} is chosen from the series consisting of phenyl and an aromatic 5-membered or 6-membered monocyclic heterocycle which comprises one, two or three identical or different ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur and is bonded via a ring carbon atom, wherein the phenyl and the heterocycle all are optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, $(C_1$-$C_6)$-alkyl, $(C_3$-$C_7)$-cycloalkyl, HO-, $(C_1$-$C_6)$-alkyl-O-, -O-CH_2-O-, -O-CF_2-O-, $(C_1$-$C_6)$-alkyl-$S(O)_m$-, H_2N-$S(O)_2$-, $(C_1$-$C_4)$-alkyl-NH-$S(O)_2$-, di$((C_1$-$C_4)$-alkyl)N-$S(O)_2$-, H_2N-, $(C_1$-$C_6)$-alkyl-NH-, di$((C_1$-$C_6)$-alkyl)N-, $(C_1$-$C_4)$-alkyl-C(O)-NH-, $(C_1$-$C_4)$-alkyl-$S(O)_2$-NH- and NC-;

R^{40} is hydrogen.

4. A compound of the formula I, in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, as claimed in any one or more of claims 1 to 3, wherein
R^{50} is hydrogen;
R^{60} is hydrogen.

5. A compound of the formula I, in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, as claimed in any one or more of claims 1 to 4, wherein
R^{30} is R^{32}-C_uH_{2u}- wherein u is an integer 0;
R^{40} is hydrogen,

6. A compound of the formula I, in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, as claimed in any one or more of claims 1 to 5, wherein the compound is chosen from
3-Cyclohexyl-3-[(5-methyl-2-phenyl-oxazole-4-carbonyl)-amino]-propionic acid
3-[(5-Methyl-2-phenyl-oxazole-4-carbonyl)-amino]-4-phenyl-butyric acid
(S)-3-[(5-Methyl-2-phenyl-oxazole-4-carbonyl)-amino]-3-o-tolyl-propionic acid
(S)-3-(2-Fluoro-phenyl)-3-[(5-methyl-2-phenyl-oxazole-4-carbonyl)-amino]-propionic acid
(S)-3-(3-Fluoro-phenyl)-3-[(5-methyl-2-phenyl-oxazole-4-carbonyl)-amino]-propionic acid
(S)-3-(4-Fluoro-phenyl)-3-[(5-methyl-2-phenyl-oxazole-4-carbonyl)-amino]-propionic acid
(S)-3-{[2-(2-Fluoro-phenyl)-5-methyl-oxazole-4-carbonyl]-amino}-3-phenyl-propionic acid
(S)-3-[(5-Isopropyl-2-phenyl-oxazole-4-carbonyl)-amino]-3-phenyl-propionic acid
(S)-3-(4-Methoxy-phenyl)-3-[(5-methyl-2-phenyl-oxazole-4-carbonyl)-amino]-propionic acid
(S)-3-(3-Methoxy-phenyl)-3-[(5-methyl-2-phenyl-oxazole-4-carbonyl)-amino]-propionic acid
(S)-3-{[2-(2-Fluoro-phenyl)-5-methyl-oxazole-4-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-{[2-(2-Fluoro-phenyl)-5-methyl-oxazole-4-carbonyl]-amino}-3-m-tolyl-propionic acid

(S)-3-(3-Chloro-phenyl)-3-[(5-methyl-2-phenyl-oxazole-4-carbonyl)-amino]-propionic acid

(R)-3-{[2-(2-Fluoro-phenyl)-5-methyl-oxazole-4-carbonyl]-amino}-4-phenyl-butyric acid

(S)-3-{[2-(2-Fluoro-phenyl)-5-methyl-oxazole-4-carbonyl]-amino}-3-phenyl-butyric acid

(S)-3-(2-Chloro-phenyl)-3-[(5-methyl-2-phenyl-oxazole-4-carbonyl)-amino]-propionic acid

(3-Cyclohexyl-3-[(5-isopropyl-2-phenyl-oxazole-4-carbonyl)-amino]-propionic acid

(S)-3-(2-Fluoro-phenyl)-3-{[2-(2-fluoro-phenyl)-5-methyl-oxazole-4-carbonyl]-amino}-propionic acid

(S)-3-(3-Fluoro-phenyl)-3-{[2-(2-fluoro-phenyl)-5-methyl-oxazole-4-carbonyl]-amino}-propionic acid

(S)-3-(4-Fluoro-phenyl)-3-{[2-(2-fluoro-phenyl)-5-methyl-oxazole-4-carbonyl]-amino}-propionic acid

3-[(5-Isopropyl-2-phenyl-oxazole-4-carbonyl)-amino]-4-phenyl-butyric acid

(S)-3-(2-Fluoro-phenyl)-3-[(5-isopropyl-2-phenyl-oxazole-4-carbonyl)-amino]-propionic acid

(S)-3-(4-Fluoro-phenyl)-3-[(5-isopropyl-2-phenyl-oxazole-4-carbonyl)-amino]-propionic acid

(S)-3-(3-Chloro-phenyl)-3-{[2-(2-fluoro-phenyl)-5-methyl-oxazole-4-carbonyl]-amino}-propionic acid

3-(2-Chloro-phenyl)-3-{[2-(2-fluoro-phenyl)-5-methyl-oxazole-4-carbonyl]-amino}-propionic acid

(S)-3-(4-Chloro-phenyl)-3-{[2-(2-fluoro-phenyl)-5-methyl-oxazole-4-carbonyl]-amino}-propionic acid

(S)-3-[(5-Isopropyl-2-phenyl-oxazole-4-carbonyl)-amino]-3-(3-methoxy-phenyl)-propionic acid

(S)-3-(2,3-Dimethoxy-phenyl)-3-[(5-methyl-2-phenyl-oxazole-4-carbonyl)-amino]-propionic acid

(S)-3-(2-Chloro-phenyl)-3-[(5-isopropyl-2-phenyl-oxazole-4-carbonyl)-amino]-propionic acid

3-Cyclohexyl-3-[(2-phenyl-5-trifluoromethyl-oxazole-4-carbonyl)-amino]-propionic acid

(S)-3-(2,4-Dichloro-phenyl)-3-[(5-methyl-2-phenyl-oxazole-4-carbonyl)-amino]-propionic acid

(S)-3-(2,3-Dichloro-phenyl)-3-[(5-methyl-2-phenyl-oxazole-4-carbonyl)-amino]-propionic acid

(S)-3-[(2-Phenyl-5-trifluoromethyl-oxazole-4-carbonyl)-amino]-3-o-tolyl-propionic acid

(S)-3-[(5-Methyl-2-phenyl-oxazole-4-carbonyl)-amino]-3-(2-trifluoromethyl-phenyl)-propionic acid

(S)-3-(3-Fluoro-phenyl)-3-[(2-phenyl-5-trifluoromethyl-oxazole-4-carbonyl)-amino]-propionic acid

(S)-3-{[2-(2-Fluoro-phenyl)-5-methyl-oxazole-4-carbonyl]-amino}-3-(3-trifluoromethyl-phenyl)-propionic acid

(S)-3-{[2-(2-Fluoro-phenyl)-5-methyl-oxazole-4-carbonyl]-amino}-3-(4-trifluoromethyl-phenyl)-propionic acid

(S)-3-(2,3-Dichloro-phenyl)-3-{[2-(2-fluoro-phenyl)-5-methyl-oxazole-4-carbonyl]-amino}-propionic acid

(S)-3-(3-Chloro-phenyl)-3-[(2-phenyl-5-trifluoromethyl-oxazole-4-carbonyl)-amino]-propionic acid

(S)-3-(2-Chloro-phenyl)-3-[(2-phenyl-5-trifluoromethyl-oxazole-4-carbonyl)-amino]-propionic acid

(S)-3-(2,3-Dichloro-phenyl)-3-[(5-isopropyl-2-phenyl-oxazole-4-carbonyl)-amino]-propionic acid


(S)-3-(2,4-Dichloro-phenyl)-3-[(5-isopropyl-2-phenyl-oxazole-4-carbonyl)-amino]-propionic acid

(S)-3-(2,3-Dimethoxy-phenyl)-3-[(2-phenyl-5-trifluoromethyl-oxazole-4-carbonyl)-amino]-propionic acid

(S)-3-(2,3-Dichloro-phenyl)-3-[(2-phenyl-5-trifluoromethyl-oxazole-4-carbonyl)-amino]-propionic acid

(S)-3-(2,4-Dichloro-phenyl)-3-[(2-phenyl-5-trifluoromethyl-oxazole-4-carbonyl)-amino]-propionic acid

7. A process for the preparation of a compound of the formula I or a physiologically acceptable salt thereof as claimed in any one or more of claims 1 to 6, comprising reacting a compound of the formula II with a compound of the formula III,



II III I

wherein the groups Ht, G, R^{10}, R^{11}, R^{30}, R^{40}, R^{50} and R^{60} in the compounds of the formulae II and III are defined as in the compounds of the formula I and the group J in the compound of the formula II is HO-, (C_1-C_4)-alkyl-O- or halogen.

8. A compound of the formula I as claimed in any one or more of claims 1 to 6 or a physiologically acceptable salt thereof for use as a pharmaceutical.

9. A pharmaceutical composition, which comprises at least one compound of the formula I as claimed in any one or more of claims 1 to 6 or a physiologically acceptable salt thereof and a pharmaceutically acceptable carrier.

10. Use of a compound of the formula I as claimed in any one or more of claims 1 to 6 or a physiologically acceptable salt thereof for the manufacture of a medicament for the treatment of heart failure, congestive heart failure, cardiomyopathy, myocardial infarction, left ventricular dysfunction, cardiac hypertrophy, valvular heart diseases, hypertension, atherosclerosis, peripheral arterial occlusive disease, restenosis, vasvular permeability disorders, treatment of edema, thrombosis, rheumatoid arthritis, osteoarthritis, renal failure, cystic fibrosis, chronic bronchitis, chronic obstructive pulmonary disease, asthma, immunological diseases, diabetic complications, fibrotic diseases, pain, ischemia or reperfusion damage or neurodegenerative diseases, or for cardioprotection or renoprotection or as a diuretic (stand-alone treatment or in combination with established diuretics).